Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence

Pancreatic cancer is one of the leading causes of cancer-related deaths in developed countries [1]. Incidence rates vary between regions, with the highest in North America (7.4 per 100,000 people in 2012) and Western Europe (7.3 per 100,000) [1]. Mortality rates are almost as high as incidence rates (6.9 per 100,000 in North America and 6.8 per 100,000 in Western Europe), reflecting how lethal pancreatic cancer is [1]. Despite being the 11th most common cancer worldwide [1], it is the 4th most fatal cancer in both men (after lung, colorectal and prostate cancers) and women (after breast, colorectal and lung cancers) [2,3], with a 5-year survival rate of less than 5% [1].

Source: Cancer Treatment Reviews - May 28, 2019 Category: Cancer & Oncology Authors: Thomas Seufferlein, Pascal Hammel, Jean Robert Delpero, Teresa Macarulla, Per Pfeiffer, Gerald W. Prager, Michele Reni, Massimo Falconi, Philip A. Philip, Eric Van Cutsem Tags: Anti-Tumour Treatment Source Type: research